A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)

被引：11

作者：

Zhou, Caicun ^{[1
]}

Hu, Yanping

Arkania, Ekaterine ^{[3
]}

Kilickap, Saadettin ^{[4
,21
]}

Ying, Kejing ^{[5
]}

Xu, Fei ^{[6
]}

Wu, Lin ^{[7
]}

Wang, Xiang ^{[8
]}

Viguro, Maksym ^{[20
]}

Makharadze, Tamta ^{[3
]}

Sun, Hongmei ^{[9
]}

Luo, Feng ^{[10
]}

Shi, Jianhua ^{[11
]}

Zang, Aimin ^{[12
]}

Pan, Yueyin ^{[13
]}

Chen, Zhendong ^{[14
]}

Jia, Zhongyao ^{[15
]}

Kuchava, Vladimer ^{[16
]}

Lu, Ping ^{[17
]}

Zhang, Ling ^{[18
]}

Cheng, Ying ^{[19
]}

Kang, Wenying ^{[20
]}

Wang, Qingyu ^{[19
]}

Yu, Haoyu ^{[20
]}

Li, Jing ^{[1
,20
]}

Zhu, Jun ^{[20
]}

机构：

[1] Shanghai Pulm Hosp, Dept Med Oncol, Shanghai 200433, Peoples R China

[2] Hubei Canc Hosp, Dept Med Oncol, Wuhan 430000, Peoples R China

[3] LTD Israeli Georgian Med Res Clin Helsicore, GE-0112 Tbilisi, Georgia

[4] Hacettepe Univ, Fac Med, Dept Med Oncol, TR-06230 Ankara, Turkiye

[5] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Pneumol, Hangzhou 310016, Peoples R China

[6] Nanchang Univ, Affiliated Hosp 1, Dept Pneumol, Nanchang 330006, Peoples R China

[7] Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Dept Thorac Med Oncol,Xiangya Sch Med, Changsha 410013, Peoples R China

[8] Xuzhou Cent Hosp, Dept Med Oncol, Xuzhou 221009, Peoples R China

[9] Jiamusi Tumor Hosp, Dept Med Oncol, Jiamusi 154007, Peoples R China

[10] Sichuan Univ, West China Hosp, Lung Canc Ctr, Chengdu 610041, Peoples R China

[11] Linyi Canc Hosp, Dept Med Oncol, Linyi 276000, Peoples R China

[12] Hebei Univ, Affiliated Hosp, Dept Med Oncol, Baoding 071000, Peoples R China

[13] Univ Sci & Technol China, Anhui Prov Hosp, Affiliated Hosp 1, Dept Med Oncol, Hefei 230001, Peoples R China

[14] Anhui Med Univ, Affiliated Hosp 2, Dept Med Oncol, Hefei 230601, Peoples R China

[15] Linyi Peoples Hosp, Dept Oncol, Linyi 276002, Peoples R China

[16] LTD Inst Clin Oncol, GE-0159 Tbilisi, Georgia

[17] Xinxiang Med Univ, Affiliated Hosp 1, Dept Oncol, Xinxiang 453100, Peoples R China

[18] Nanchang Univ, Affiliated Hosp 1, Dept Oncol, Nanchang 330006, Peoples R China

[19] Jilin Canc Hosp, Dept Oncol, Changchun 130012, Peoples R China

[20] Shanghai Henlius Biotech Inc, Shanghai 200233, Peoples R China

[21] Istinye Univ, Fac Med, Dept Med Oncol, TR-34010 Istanbul, Turkiye

来源：

CANCER CELL | 2024年 / 42卷 / 02期

关键词：

NAB-PACLITAXEL; GEMCITABINE; CARBOPLATIN; PLACEBO; TRIAL;

D O I：

10.1016/j.ccell.2023.12.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Combining immunotherapy with chemotherapy can provide improved survival in advanced squamous nonsmall -cell lung cancer (NSCLC) patients without targetable gene alterations. 537 previously untreated patients with stage IIIB/IIIC or IV squamous NSCLC without targetable gene alterations were enrolled and randomized (2:1) to receive serplulimab 4.5 mg/kg or placebo, both in combination with nab-paclitaxel and carboplatin, intravenously in 3 -week cycles. The primary endpoint of progression -free survival (PFS) was met at the first interim analysis. At the second interim analysis, PFS benefit was maintained in serplulimab-chemotherapy group (hazard ratio [HR] 0.53, 95% confidence interval [CI] 0.42-0.67). At the final analysis, serplulimab-chemotherapy significantly improved median OS compared to placebo -chemotherapy (HR 0.73, 95% CI 0.58-0.93; p = 0.010). Grade R3 serplulimab or placebo -related adverse events occurred in 126 (35.2%) and 58 (32.4%) patients, respectively. Our results demonstrate that adding serplulimab to chemotherapy significantly improves survival in advanced squamous NSCLC patients, with manageable safety.

引用

页码：198 / 208.e3

页数：15

共 50 条

[21] Pemetrexed as the first-line therapy for Chinese patients with advanced non-squamous non-small-cell lung cancer
Xu, Bei
Liu, Peng
Yin, Yongmei
Liu, Ping
Shu, Yongqian
BIOMEDICINE & PHARMACOTHERAPY, 2013, 67 (08) : 763 - 769
[22] Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer
Socinski, M. A.
CURRENT ONCOLOGY, 2014, 21 (05) : E691 - E703
[23] Effectiveness and Safety of Adding Bevacizumab to Platinum-Based Chemotherapy as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis
Liu, Yi
Li, Hui-Min
Wang, Ran
FRONTIERS IN MEDICINE, 2021, 8
[24] Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial
Wang, J.
Lu, S.
Yu, X.
Hu, Y.
Zhao, J.
Sun, M.
Yu, Y.
Hu, C.
Yang, K.
Song, Y.
Lin, X.
Liang, L.
Leaw, S.
Zheng, W.
ESMO OPEN, 2024, 9 (10)
[25] Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer
Niho, Seiji
Kunitoh, Hideo
Nokihara, Hiroshi
Horai, Takeshi
Ichinose, Yukito
Hida, Toyoaki
Yamamoto, Nobuyuki
Kawahara, Masaaki
Shinkai, Tetsu
Nakagawa, Kazuhiko
Matsui, Kaoru
Negoro, Shunichi
Yokoyama, Akira
Kudoh, Shinzoh
Kiura, Katsuyuki
Mori, Kiyoshi
Okamoto, Hiroaki
Sakai, Hiroshi
Takeda, Koji
Yokota, Soichiro
Saijo, Nagahiro
Fukuoka, Masahiro
LUNG CANCER, 2012, 76 (03) : 362 - 367
[26] Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Rizvi, Naiyer A.
Hellmann, Matthew D.
Brahmer, Julie R.
Juergens, Rosalyn A.
Borghaei, Hossein
Gettinger, Scott
Chow, Laura Q.
Gerber, David E.
Laurie, Scott A.
Goldman, Jonathan W.
Shepherd, Frances A.
Chen, Allen C.
Shen, Yun
Nathan, Faith E.
Harbison, Christopher T.
Antonia, Scott
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (25) : 2969 - +
[27] A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Paz-Ares, Luis
Balint, Beatrix
de Boer, Richard H.
van Meerbeeck, Jan P.
Wierzbicki, Rafal
De Souza, Paul
Galimi, Francesco
Haddad, Vincent
Sabin, Tony
Hei, Yong-jiang
Pan, Yang
Cottrell, Susan
Hsu, Cheng-Pang
RamLau, Rodryg
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (03) : 329 - 337
[28] Phase II study of nedaplatin and amrubicin as first-line treatment for advanced squamous cell lung cancer
Taniguchi, Hirokazu
Yamaguchi, Hiroyuki
Dotsu, Yosuke
Shimada, Midori
Gyotoku, Hiroshi
Senju, Hiroaki
Takemoto, Shinnosuke
Kitazaki, Takeshi
Fukuda, Masaaki
Ogawara, Daiki
Soda, Hiroshi
Nakatomi, Katsumi
Sugasaki, Nanae
Kinoshita, Akitoshi
Nagashima, Seiji
Ikeda, Takaya
Nakamura, Yoichi
Sakamoto, Noriho
Obase, Yasushi
Fukuda, Minoru
Mukae, Hiroshi
THORACIC CANCER, 2019, 10 (09) : 1764 - 1769
[29] Economic evaluation of serplulimab plus chemotherapy as the first-line treatment of oesophageal squamous cell carcinoma in China
Chen, Fang
Long, Yunchun
Yang, Jiayong
Zhong, Kailong
Liu, Bili
BMJ OPEN, 2023, 13 (12):
[30] Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer
Reck, Martin
IMMUNOTHERAPY, 2018, 10 (02) : 93 - 105

← 1 2 3 4 5 →